Trial Profile

A Phase 1 Dose-Escalation and Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 14 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs WU-CART-007 (Primary) ; Cyclophosphamide; Fludarabine
Indications Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Allotera Therapeutics; WUGEN

08 Jul 2026 According to Allotera Therapeutics media release, WUGEN is now called Allotera Therapeutics.
21 Jan 2026 According to a WUGEN media release, based on results of this trial the U.S. Food and Drug Administration (FDA) has given Breakthrough Therapy Designation to WU-CART-007 for the treatment of T cell malignancies.
05 Dec 2025 Results presented in the WUGEN Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com